Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Purchased by Old West Investment Management LLC

Old West Investment Management LLC lifted its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 11.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 380,240 shares of the biopharmaceutical company’s stock after buying an additional 39,799 shares during the period. Amicus Therapeutics makes up approximately 1.5% of Old West Investment Management LLC’s investment portfolio, making the stock its 23rd biggest holding. Old West Investment Management LLC’s holdings in Amicus Therapeutics were worth $3,582,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in FOLD. Wellington Management Group LLP increased its holdings in Amicus Therapeutics by 18.8% in the 4th quarter. Wellington Management Group LLP now owns 28,461,994 shares of the biopharmaceutical company’s stock worth $268,112,000 after buying an additional 4,497,950 shares during the period. Norges Bank purchased a new stake in shares of Amicus Therapeutics in the 4th quarter valued at $29,033,000. Point72 Asset Management L.P. acquired a new stake in shares of Amicus Therapeutics in the third quarter worth $13,530,000. Trexquant Investment LP raised its stake in shares of Amicus Therapeutics by 101.6% during the 4th quarter. Trexquant Investment LP now owns 966,049 shares of the biopharmaceutical company’s stock valued at $9,100,000 after buying an additional 486,827 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in Amicus Therapeutics by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 29,258,963 shares of the biopharmaceutical company’s stock valued at $275,619,000 after acquiring an additional 458,143 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. StockNews.com cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, February 20th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Cantor Fitzgerald restated an “overweight” rating and set a $21.00 target price on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Wells Fargo & Company reduced their price target on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a report on Thursday, February 20th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $12.00 price objective (down from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $16.75.

Amicus Therapeutics Stock Performance

NASDAQ FOLD opened at $7.50 on Friday. The stock’s 50 day simple moving average is $9.12 and its 200-day simple moving average is $9.86. Amicus Therapeutics, Inc. has a 1-year low of $7.39 and a 1-year high of $12.65. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42. The company has a market cap of $2.30 billion, a PE ratio of -41.67, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.